Clinical Trial Update: A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy [Phase 2, Phase 3]

View source ↗

Summary

This update covers a long-term, safety study of KW-6002 (istradefylline) across a flexible dose range in Parkinson's disease patients with motor fluctuations on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Nourianz (istradefylline) (istradefylline)

Snippet

Sponsor: Kyowa Kirin, Inc. | Conditions: Parkinson's Disease | Phase 2, Phase 3 | Status: COMPLETED